Ashwagandha faces its biggest regulatory test yet in Europe
Europe is deciding whether ashwagandha should undergo an EFSA Article 8 review, and what that would mean for formulators and brands.
What's inside
Ashwagandha sits on a regulatory knife-edge in Europe. An EFSA Article 8 review could restrict or reshape how the ingredient is marketed and dosed across the EU. This newsletter sets out where the review stands, which claims are most exposed, and how formulators should prepare while the decision is still open.
Read the full newsletter
Fill in your details and we'll email your copy as soon as it's published.
Home
Our story, capacity and what makes Benova Healthcare a one-stop CDMO partner.
Product catalogue
Market-ready formulations across seven formats. Private label or custom.
Our process
Five integrated stages from formulation to delivery, all under one roof.
Quality & certifications
GMP-certified manufacturing, on-site laboratory testing and batch-level traceability.
About us
The team, the facility and the structural advantages behind our work.